Skip to content
value.today

BioStem Technologies, Inc.

BSEM
$29 Mmarket cap on Oct 29, 2026
Compare
World rank
#23,195
Revenue
$47 M
For year ending December-2025
Net income
$-7 M
-13.9% margin
SEC filing
Employees
—

BioStem Technologies, Inc. in brief

BioStem Technologies, Inc. is a listed company in the Biotechnology industry, based in Pompano Beach, Florida, USA. Its market value was $29 M on 29 October 2026, which makes it the 23,195th largest listed company in the world and the 4,052nd largest in the USA on this site. In the year to December 2025 it had sales of $47 M and a net loss of $7 M. Jason Matuszewski is its chief executive. Its shares trade under the symbol BSEM (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

BioStem Technologies, Inc. timeline

1 events, 2016
  1. 2016
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.

Events of BioStem Technologies, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$15 M$31 M$46 M$62 M2020202120222023202420252026

World rank over time

▲ up 1,103 places since 2020
2020-01-01: #24328#24,32820202021-01-01: #22713#22,71320212022-01-07: #34060#34,06020222022-12-25: #27417#27,41720222023-07-30: #28457#28,45720232026-08-01: #19081#19,08120262026-10-14: #21871#21,87120262026-10-29: #23225#23,2252026

Rank in USA: #4,413 (Jan 2020) · #4,335 (Jan 2021) · #5,641 (Jan 2022) · #5,056 (Dec 2022) · #5,093 (Jul 2023) · #3,688 (Aug 2026) · #3,896 (Oct 2026) · #4,055 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.7×
Price / book
0.7×
Free cash flow yield
22.8%
Net margin (TTM)
-66.6%
Operating margin
-1.5%
Return on equity
-70.8%
Liabilities / assets
21.8%
Net debt
$-30M
Revenue growth
-31.8%
R&D / revenue
14.9%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2024: revenue $70M, net income $31M$70MFY24Fiscal year ending Dec 2025: revenue $47M, net income $-7M$47MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$47M-31.8%$-1M$-7M-13.9%
Dec 2024$70M—$31M$31M44.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$10M$3M$7M$-0.39—
Dec 2024$24M$0M$24M$1.43—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$42M
Net income, trailing 12 months
$-28M
RevenueNet income
Three months to Jun 2025: revenue $11M, net income $0M$11MJun ’25Three months to Sep 2025: revenue $10M, net income $1M$10MSep ’25Three months to Jun 2026: revenue $8M, net income $-9M$8MJun ’26Three months to Sep 2026: revenue $8M, net income $-11M$8MSep ’26

Latest quarter to Sep 2026: revenue $8M (-27.0% on a year earlier), net income $-11M. Trailing 12 months to Sep 2026.

SEC filings

Official filings of BioStem Technologies, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$47 M
Operating income
$-1 M
Net income
$-7 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$50 M
Total liabilities
$11 M
Total equity
$39 M

As of December-2025

Top 26 institutional investors in BioStem Technologies, Inc.#

As of Sep 30, 2026
26 institutions held 1.8 M shares (about 9.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 9.0%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in BioStem Technologies, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1PNC Financial Services Group, Inc.543,847New2.84%$2 MNov 6, 2026
2Vanguard Capital Management LLC484,811New2.53%$1 MNov 13, 2026
3Anson Funds Management LP367,648New1.92%$1 MNov 13, 2026
4Geode Capital Management, LLC141,388New0.74%$0 MNov 6, 2026
5Vanguard Fiduciary Trust Co81,753New0.43%$0 MNov 13, 2026
6Northern Trust Corp33,421New0.17%$0 MNov 16, 2026
7Millennium Management LLC23,990New0.13%$0 MNov 16, 2026
8UBS Group AG19,969New0.10%$0 MNov 10, 2026
9Virtu Financial LLC18,830New0.10%$0 MNov 17, 2026
10StoneX Group Inc.18,251New0.10%$0 MNov 3, 2026
11Elequin Capital, LP10,614New0.06%$0 MNov 13, 2026
12Ashton Thomas Private Wealth, LLC10,078New0.05%$0 MNov 3, 2026
13Vanguard Global Advisers, LLC6,961New0.04%$0 MNov 13, 2026
14Beaird Harris Wealth Management, LLC2,000New0.01%$0 MNov 13, 2026
15Osaic Holdings, Inc.1,550New0.01%$0 MNov 12, 2026
16Tower Research Capital LLC (TRC)760New0.00%$0 MNov 16, 2026
17Atlantic Union Bankshares Corp500New0.00%$0 MNov 12, 2026
18Gables Capital Management Inc.350New0.00%$0 MNov 4, 2026
19Wolff Wiese Magana LLC350New0.00%$0 MOct 15, 2026
20HighMark Wealth Management LLC250New0.00%$0 MNov 17, 2026
21Global Retirement Partners, LLC200New0.00%$0 MNov 10, 2026
22Birchbrook, Inc.200New0.00%$0 MOct 14, 2026
23FMR LLC100New0.00%$0 MNov 10, 2026
24Jpmorgan Chase & Co79New0.00%$0 MNov 12, 2026
25Allworth Financial LP74New0.00%$0 MNov 17, 2026
Show all 26: investors 26 to 26
Institutional investors 26 to 26 in BioStem Technologies, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Federation des caisses Desjardins du Quebec1New0.00%$0 MNov 16, 2026

Insider trading at BioStem Technologies, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
10
since
BioStem Technologies, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Brandon PoeChief Financial OfficerOption exercise+2,699——60,763Form 4
filed Michael A. FortunatoChief Accounting OfficerOption exercise+970——69,634Form 4
filed Barry HassettChief Commercial OfficerOption exercise+253——5,256Form 4
filed Jason MatuszewskiChief Executive Officer, Director, 10% ownerOption exercise+250,000$2.000$500 K1.55 MForm 4
filed Vurst Andrew Smith-VanChief Operating Officer, Director, 10% ownerOption exercise+250,000$2.000$500 K1.79 MForm 4
filed Jason MatuszewskiChief Executive Officer, Director, 10% ownerOption exercise+16,650——1.30 MForm 4
filed Vurst Andrew Smith-VanChief Operating Officer, Director, 10% ownerOption exercise+9,574——1.54 MForm 4
filed Jason MatuszewskiChief Executive Officer, Director, 10% ownerOption exercise+8,469——1.29 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: BioStem Technologies, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
286,950
1.7% of shares · 1.53 days to cover
Shares sold short, last 24 reportsAll stocks →

IPO: registered (S-1), not yet priced · IPO calendar

Trading halts

  • 2026-08-13 13:30 UTC, code LUDP, resumed 13:35 UTC

Fails to deliver

  • : 9 shares at $1.51
  • : 188,086 shares at $1.54
  • : 140,882 shares at $1.57
  • : 109,141 shares at $1.66
  • : 102,141 shares at $1.68

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

BioStem Technologies, Inc. scorecard#

Passes 9 of the 15 checks that could be worked out: strongest in financial health (4 of 4), weakest in profitability (1 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation3 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.7×Price to book 0.7× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median0.7×Price to sales 0.7× against Biotechnology's median of 8.7×.
    • ✓Free cash flow yield above 5%22.8%Free cash flow is 22.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'No revenue growth over three years on file.
  • Growth0 of 2
    • ✗Revenue grew in the newest year-31.8%Revenue down 31.8% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.39 vs 1.43Diluted EPS -0.39 in fiscal 2025 against 1.43 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability1 of 3
    • ✗Profitable in the newest year-$7 MNet income -$7 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✓Operating margin above its peers' median-1.4%-1.4% against Biotechnology's median of -60.5% (243 companies).
    • ✗Return on equity above 15%-16.6%-16.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health4 of 4
    • ✓Short-term assets cover short-term liabilities4.1×Current ratio 4.12 at the end of fiscal 2025.
    • ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $30 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • ✓Altman Z-score outside the distress zone2.71Z-score 2.71 (grey zone) for fiscal 2025.
  • Shareholder returns1 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year-22.9%Diluted shares down 22.9% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from BioStem Technologies, Inc.'s statements, beside the median of Biotechnology.

BioStem Technologies, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-1.5%-60.5%
Net margin-13.9%-68.9%
Return on equity-16.6%-61.0%
Revenue growth-31.8%15.8%
Debt to equity0.00×0.26×
Free cash flow margin13.9%-61.5%

5of 9on the Piotroski tests of financial strength

  • Revenue fell 31.8% against the year before.
  • Net loss of $7 million.
  • The share count fell 22.9% in the year (buybacks).
  • More cash than debt: net cash of $30 million.

Events at BioStem Technologies, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Material agreement 2 · Unregistered share sale 2 · Results announced 2

BioStem Technologies, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of BioStem Technologies, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2026$3 MPrivate placement after listing$2 to $10 million2equity, optionsSEC
May 2026$3 MPrivate placement after listing$2 to $10 million1equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by BioStem Technologies, Inc.#

$430 K spent on lobbying the US Congress and federal agencies in 2025, most often on medicare/medicaid.

Lobbying, 2025
$430 K
#658 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$180 K
  • Medicare/Medicaid4 reports

Lobbying firms hired in 2025

BALLARD PARTNERS $430 K

BioStem Technologies, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$180 K—2
2025$430 K—4
2024$160 K—2

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “BioStem Technologies”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How BioStem Technologies, Inc. compares in Biotechnology

  • Market cap$29 M · higher than 21% of 726
  • Revenue$47 M · higher than 59% of 647
  • Net margin-66.6% · higher than 48% of 408
  • Revenue growth-31.8% · higher than 26% of 438
  • Price / sales0.7× · lower than 96% of 339
  • Price / book0.7× · lower than 84% of 534
  • FCF yield22.8% · higher than 99% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
BioStem Technologies, Inc.🇺🇸$29 M—-66.6%-31.8%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at BioStem Technologies, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show BioStem Technologies, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about BioStem Technologies, Inc.? Suggest a correction